<div id="readability-page-1"><p>New York State Common Retirement Fund raised its position in  LivaNova PLC (NASDAQ:LIVN - Free Report) by 79.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 86,741 shares of the company's stock after acquiring an additional 38,451 shares during the quarter. New York State Common Retirement Fund owned approximately 0.16% of LivaNova worth $3,905,000 at the end of the most recent quarter.</p><p>Several other institutional investors and hedge funds have also bought and sold shares of LIVN. State of Michigan Retirement System increased its position in shares of  LivaNova by 2.3% during the 2nd quarter. State of Michigan Retirement System now owns 13,111 shares of the company's stock valued at $590,000 after purchasing an additional 300 shares during the last quarter.  GAMMA Investing LLC grew its position in  LivaNova by 182.5% during the second quarter. GAMMA Investing LLC now owns 630 shares of the company's stock valued at $28,000 after buying an additional 407 shares during the period.  Central Pacific Bank Trust Division increased its holdings in  LivaNova by 9.5% during the second quarter. Central Pacific Bank Trust Division now owns 4,827 shares of the company's stock valued at $217,000 after buying an additional 420 shares during the last quarter.  Retirement Systems of Alabama raised its position in  LivaNova by 0.8% in the second quarter. Retirement Systems of Alabama now owns 66,644 shares of the company's stock worth $3,000,000 after acquiring an additional 554 shares during the period.  Finally, Inceptionr LLC boosted its stake in shares of  LivaNova by 14.1% during the 2nd quarter. Inceptionr LLC now owns 5,856 shares of the company's stock worth $264,000 after acquiring an additional 723 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors. </p><h2>Wall Street Analyst Weigh In</h2><p>Several equities research analysts have recently commented on LIVN shares. Barclays upped their price objective on LivaNova from $55.00 to $58.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Thursday, August 21st. Robert W. Baird upped their price target on LivaNova from $63.00 to $70.00 and gave the stock an &#34;outperform&#34; rating in a research report on Thursday, November 13th. The Goldman Sachs Group  set a $55.00 price objective on LivaNova and gave the stock a &#34;neutral&#34; rating in a research note on Wednesday, October 1st. Weiss Ratings  reiterated a &#34;sell (d+)&#34; rating on shares of LivaNova in a research note on Monday, December 1st. Finally, Wall Street Zen lowered shares of LivaNova from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Saturday. Five equities research analysts have rated the stock with a Buy rating, two have issued  a Hold rating and one  has issued  a Sell rating to the company's stock. According to MarketBeat.com, the company  has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $62.43.</p><p><b>Check Out Our Latest Research Report on LIVN</b></p><h2>LivaNova Price Performance</h2><p>LivaNova stock opened at $63.36 on Monday. The business has a 50 day simple moving average of $55.14 and a 200 day simple moving average of $50.93. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.33 and a quick ratio of 1.12. The company has a market capitalization of $3.46 billion, a PE ratio of -15.84 and a beta of 1.02. LivaNova PLC has a one year low of $32.48 and a one year high of $64.45. </p><h2>LivaNova Company Profile</h2> (Free Report)<p>LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than LivaNova</li><li>Stock Market Upgrades: What Are They?</li><li>Rubrik’s Massive Rebound: Why the Next Leg Higher Could Be Fast</li><li>What Are Treasury Bonds?</li><li>Five Below and Dollar Tree Earnings Signal a Shopper Shift</li><li>High Flyers: 3 Natural Gas Stocks for March 2022</li><li>Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead?</li></ul><p><strong>Want to see what other hedge funds are holding LIVN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TElWTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TElWTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in LivaNova Right Now?</h2><p>Before you consider LivaNova, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.</p><p>While LivaNova currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

LIVN

<p>New York State Common Retirement Fund increased its stake in LivaNova PLC by 79.6% in Q2, owning 86,741 shares worth $3.9M. Analysts have mixed ratings on LIVN, with a consensus "Moderate Buy" and an average price target of $62.43. LivaNova's stock opened at $63.36, with a market cap of $3.46B.</p>

New York State Common Retirement Fund Purchases 38,451 Shares of LivaNova PLC $LIVN